Paclitaxel is a mitotic inhibitor used in Cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".

Market Analysis and Insights: Global Paclitaxel API Market
The global Paclitaxel API market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Paclitaxel API Scope and Market Size
The global Paclitaxel API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Paclitaxel API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Natural Paclitaxel API
Semi-synthetic Paclitaxel API

Segment by Application
Ovarian Cancer
Cervical Cancer
Breast Cancer
Other

The Paclitaxel API market is analysed and market size information is provided by regions (countries). Segment by Application, the Paclitaxel API market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Phyton
ScinoPharm
Novasep
Samyang
Polymed
TAPI (Teva)
Fresenius-kabi
Huiang biopharma
Southpharma
Yunnan Hande
Hainan Yew Pharm
Jiangsu Yew Biotechnology